Cetuximab (PBS) 

Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the K_d value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect^[1].

Cetuximab (PBS) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a K_d of 0.147 nM for EGFR in fixed A431 cells by ELISA^[1].
Cetuximab (PBS) (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (PBS) (30 nM) causes G₀/G₁ arrest, induces apoptosis, and reduces Rb, p27^KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (PBS) (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cetuximab (PBS) (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab significantly reduces the expression of EGFR, pEGFR and Ki67. Cetuximab (PBS) significantly decreases the expression in the MCT1 and GLUT1 cells but differences are more pronounced in UT-SCC-14 xenografts^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.54 kDa

Liquid

Colorless to light yellow

[Cetuximab (PBS)]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Immobilized EGFR Protein, Human can bind Cetuximab (PBS). The EC₅₀ for this effect is 1.68 ng/mL.

• [1]. Goldstein, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clinical cancer research: an official journal of the American Association for Cancer Research 1.11 (1995): 1311-1318.  [Content Brief]

  [2]. Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29.  [Content Brief]

  [3]. Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40.  [Content Brief]